Eric Devroe
Direttore operativo presso ACRIVON THERAPEUTICS, INC.
Patrimonio netto: 585 252 $ in data 30/04/2024
Profilo
Eric J.
Devroe was the founder of Opsonix, Inc. (founded in 2015) where he served as the Chief Executive Officer & Director from 2015 to 2018.
Dr. Devroe is also the founder of Xione Therapeutics, Inc...
Dr. Devroe's current job is as the Chief Operating Officer at Acrivon Therapeutics, Inc. since 2022.
Dr. Devroe's former jobs include working as a Scientist at Asuragen, Inc., as a Principal at Codon Devices, Inc., and as the VP-Business & Strategy Development at Metamark Genetics, Inc. Dr. Devroe's education includes a doctorate degree from Harvard University and an undergraduate degree from The University of Texas at Austin.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 17/05/2024 | 69 097 ( 0.22% ) | 585 252 $ | 30/04/2024 |
Posizioni attive di Eric Devroe
| Società | Posizione | Inizio |
|---|---|---|
| ACRIVON THERAPEUTICS, INC. | Direttore operativo | 01/08/2022 |
Precedenti posizioni note di Eric Devroe
| Società | Posizione | Fine |
|---|---|---|
Opsonix, Inc.
 Opsonix, Inc. Medical SpecialtiesHealth Technology Opsonix, Inc. manufactures and distributes medical devices. It commercializes and develops products to transform the treatment and diagnosis of sepsis. The company was founded on April 11, 2014 and is headquartered in Cambridge, MA. | Fondatore | 01/01/2018 |
Xione Therapeutics, Inc.
 Xione Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xione Therapeutics, Inc. engages in the provision of biotechnology services. The company is headquartered in Houston, TX. | Amministratore Delegato | - |
Codon Devices, Inc.
 Codon Devices, Inc. Pharmaceuticals: MajorHealth Technology Codon Devices, Inc. produces pharmaceuticals and biorefineries for the production of industrial chemicals and bio-energy. The firm designs and constructs biological components such as enzymes, biopharmaceuticals, and cell lines for improved function. Its customers include the biotechnology, pharmaceutical, and agriculture sectors. The company was founded by Noubar B. Afeyan, George Church, Drew Endy, Joseph M. Jacobson and Jay Keasling in 2004 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Asuragen, Inc.
 Asuragen, Inc. Medical SpecialtiesHealth Technology Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX. | Corporate Officer/Principal | - |
Metamark Genetics, Inc.
 Metamark Genetics, Inc. Medical/Nursing ServicesHealth Services Metamark Genetics, Inc. provides molecular diagnostics services. It develops prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients. It transforms cancer diagnosis and treatment by developing pioneering diagnostic products based on its prognosis determinants platform. The company was founded by Kenneth E. Weg, Raju S. Kucherlapati, David Rimm, Lynda Chin and Ronald A. DePinho in November 2007 and is headquartered in Waltham, MA. | Direttore operativo | 23/03/2011 |
Formazione di Eric Devroe
| The University of Texas at Austin | Undergraduate Degree |
| Harvard University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Metamark Genetics, Inc.
Metamark Genetics, Inc. Medical/Nursing ServicesHealth Services Metamark Genetics, Inc. provides molecular diagnostics services. It develops prognostic and predictive diagnostic tests that will enable personalized treatment planning for cancer patients. It transforms cancer diagnosis and treatment by developing pioneering diagnostic products based on its prognosis determinants platform. The company was founded by Kenneth E. Weg, Raju S. Kucherlapati, David Rimm, Lynda Chin and Ronald A. DePinho in November 2007 and is headquartered in Waltham, MA. | Health Services |
Codon Devices, Inc.
Codon Devices, Inc. Pharmaceuticals: MajorHealth Technology Codon Devices, Inc. produces pharmaceuticals and biorefineries for the production of industrial chemicals and bio-energy. The firm designs and constructs biological components such as enzymes, biopharmaceuticals, and cell lines for improved function. Its customers include the biotechnology, pharmaceutical, and agriculture sectors. The company was founded by Noubar B. Afeyan, George Church, Drew Endy, Joseph M. Jacobson and Jay Keasling in 2004 and is headquartered in Cambridge, MA. | Health Technology |
Asuragen, Inc.
Asuragen, Inc. Medical SpecialtiesHealth Technology Asuragen, Inc. develops molecular diagnostic products. Its products include AmplideX and QuantideX. It uses genomics to drive patient management through clinical testing solutions. The company was founded in March 2006 by Matthew M. Winkler and is headquartered in Austin, TX. | Health Technology |
Opsonix, Inc.
Opsonix, Inc. Medical SpecialtiesHealth Technology Opsonix, Inc. manufactures and distributes medical devices. It commercializes and develops products to transform the treatment and diagnosis of sepsis. The company was founded on April 11, 2014 and is headquartered in Cambridge, MA. | Health Technology |
Xione Therapeutics, Inc.
Xione Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xione Therapeutics, Inc. engages in the provision of biotechnology services. The company is headquartered in Houston, TX. | Health Technology |
| Acrivon Therapeutics, Inc. |
- Borsa valori
- Insiders
- Eric Devroe
